NSE: DIVISLAB | BSE: 532488

Expensive Star

Download real time

6148.00 -13.00 (-0.21%)

Near 52W High of ₹6308.50

349.0K NSE+BSE Volume

NSE 07 May, 2025 3:31 PM (IST)

163,210.1

Market Cap

Market Runner Up

0.7

Beta 1Year

Very Low volatility

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Divi's Laboratories Ltd.

20 Apr 2020

6148.00

-0.21%

Divi's Laboratories

Hold: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

On the business front, despite the nationwide lockdown, domestic growth is expected to remain more or less stable. Exports growth, barring for one or two months due to congestion in all major ports globally, is also expected to remain strong due to 1) currency benefit, 2) slowdown in competition due to delay in new approvals that will be beneficial for existing players and 3) expected demand continuum across the world despite Covid-19. Some windfall is also expected in some critical productsa case in point is Hydroxychloroquine, a malaria drug that is likely to be repurposed as a prophylaxis for Covid-19 treatment in some cases....

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

05 Feb 2020

6148.00

-0.21%

Backward integration benefits offset by higher opex related to compliance

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

5 February 2020 DIVI is almost at the end of significant capacity expansion worth INR17b to cater to the increasing generics business and innovators increased outsourcing. Lower Nutraceutical sales impacted DIVIs 3QFY20 performance; however, we believe that the company is well positioned to benefit from the CRAMS opportunity over the next 4-5 years. We reduce our EPS estimate by 3%/2% for FY20/FY21E, primarily to factor in the reduction in Nutraceutical sales and the higher opex related to compliance. 3QFY20 sales grew a marginal 2.7% YoY to INR14b (v/s est. Gross margin shrank 440bp YoY to 60.8%, largely due to inferior product mix and higher raw material cost. EBITDA margin contracted at lower rate of 380bp YoY to 35.4%.

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.

Divi's Laboratories Ltd.

06 Nov 2019, 12:00AM

6148.00

-0.21%

Divi's Laboratories

Hold: Divi's Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

The custom synthesis (CS) business (42% of FY19 revenues) is a margin accretive business but at times lumpy as it depends on offtake from customers (global top 20 big pharma). However, this business has shown a good recovery on account of an improved business environment. Strong R&D; capabilities and India cost arbitrage along with IP adherence are some legacy strengths, which will drive incremental assignments from MNCs. We...

Divi's Laboratories Ltd. has gained 55.13% in the last 1 Year

Divi's Laboratories Ltd.

06 Nov 2019, 12:00AM

6148.00

-0.21%

Divi s Lab: Lower margins on account of product mix

Sell: Divi's Laboratories Ltd.

Recommendation Target

Karvy

Divis Lab s Net revenues increased by 9.2 percent YoY to Rs 14.45 bn, which ishigher than our estimates.

Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.

Divi's Laboratories Ltd.

05 Nov 2019

6148.00

-0.21%

Divi's Labs (ADD): Good Q2 beat; FY20 margin guidance cut is negative

Buy: Divi's Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Overall Revenue/EBITDA were 13% ahead of our estimates but largely in-line with consensus.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

05 Nov 2019

6148.00

-0.21%

Sales impressive, higher RM cost hurts margins

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

the product mix with a shift toward generics (59% v/s 57% YoY) and increased RM cost led to gross margin contraction of 390bp YoY to 59%. DIVI incurred non-recurring operational expense of INR200m related to power & fuel, consultancy and other regulatory costs. Adjusting for this, the EBITDA margin shrank 410bp YoY to 35.3% (our estimate: 34.2%). Accordingly, EBITDA declined 2% YoY to INR5.1b (our estimate: INR4.6b). DIVI had a forex gain of INR132m for the quarter. Adjusting for the same, PAT was down marginally by 1% YoY to INR3.6b (our estimate: INR3.4b). For 1HFY20, sales/...

Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.

Divi's Laboratories Ltd.

04 Sep 2019

6148.00

-0.21%

Initiating Coverage:Divis Lab.

Buy: Divi's Laboratories Ltd.

Target

Axis Direct

Uptrend in capital expenditure; Strong order visibility: Divi's will incur huge capital expenditure on new block at Unit 1 and Unit 2, with total capex of Rs1,700Cr; We initiate coverage on Divi's Laboratories with a BUY rating and target price of Rs1,900.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

19 Aug 2019

6148.00

-0.21%

Divis Labs

Buy: Divi's Laboratories Ltd.

Target

Sharekhan

Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.

Divi's Laboratories Ltd.

12 Aug 2019

6148.00

-0.21%

Adverse macro situation for raw materials impacts profitability

Neutral: Divi's Laboratories Ltd.

Motilal Oswal

Adverse macro situation for raw materials impacts profitability Motilal Oswal values your support in the Asiamoney Brokers Poll 2019 for...

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.

Divi's Laboratories Ltd.

12 Aug 2019

6148.00

-0.21%

Divi s Lab: Lower margins, limited upside

Hold: Divi's Laboratories Ltd.

Recommendation Target

Karvy

Divis Labs Net revenues increased by 16.8 percent YoY to Rs 11.65 bn, which is in line with our estimates. The Operating margins were at 33 percent in Q1FY20 (much lower than our estimate of 36.0 percent) as against 35.4 percent in Q1FY19 on account of lower gross margin and higher expenditure.

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.

Is Divi's Laboratories Ltd. worth buying?

745 Votes:

Buy 78.12%

Sell 14.9%

Hold 6.98%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf